Ibrexafungerp 150 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 150 mg

Reference Brands: Brexafemme (USA)

Category: Anti-fungal

Ibrexafungerp is a novel oral antifungal medication that works by inhibiting (1,3)-β-D-glucan synthase, an enzyme vital for fungal cell wall synthesis. Marketed as Brexafemme in the USA, it offers the first new oral antifungal class in over 20 years. It is primarily used to treat and prevent vulvovaginal candidiasis (yeast infections) caused by Candida species.

Product Description:

Ibrexafungerp is a triterpenoid glucan synthase inhibitor — the first antifungal in a new structural class in over twenty years. It blocks the enzyme that builds beta-1,3-D-glucan, an essential component of the fungal cell wall that human cells do not have. That is the same target as the echinocandins, but a different binding site and a different chemical class, so it retains activity against many echinocandin-resistant strains, and critically it can be given by mouth, which no echinocandin can.

It is used for vulvovaginal candidiasis, including recurrent disease, as a single-day oral course. Its value is against Candida glabrata and other non-albicans species with reduced azole susceptibility, which are an increasing problem in recurrent infection, and against azole-resistant Candida auris in wider use. It is contraindicated in pregnancy because of embryo-fetal toxicity in animals, so pregnancy must be excluded and contraception used. Nausea, diarrhoea and abdominal pain are common.

Sourcing notes. Originator product, on patent, no generic. Registration is currently US-focused. Confirm current commercial availability before committing to a quotation, as the supply position for this product has not been stable.